Brooks Laboratories Limited

NSE: BROOKS · Unclassified

₹63.25-4.82%06 Nov 2026

Ask the data

Instant answers about Brooks Laboratories Limited — computed from its filings, no language model

Market cap₹186 cr

Current price₹63.25

High / Low₹112 / ₹37

P/E14.1

P/B1.52

Book value₹41.6

ROE10.7%

ROCE4.1%

Debt / equity0.06

Dividend yield—

EPS (TTM)₹4.47

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	77.2	91.1	63.2	79.5	82.6	85.7
EBITDA	0.5	-14.4	-26.4	3.2	4.9	7.1
Operating margin	0.7%	-15.8%	-41.8%	4.1%	6.0%	8.2%
Interest	3.1	3.1	2.2	0.8	1.0	0.8
Depreciation	7.1	7.3	7.0	1.8	1.6	1.6
Profit before tax	-9.0	-23.9	-35.8	1.6	3.2	5.8
Tax	10.4	-4.6	-7.3	0.0	0.2	0.0
Net profit	-19.4	-16.2	-20.9	-19.6	-10.0	24.6
EPS ₹	6.31	-7.82	-12.57	-7.67	-3.72	8.35
Operating cash flow	—	-37.4	-14.5	-9.7	2.5	9.3
Capex	—	27.6	0.5	0.4	0.9	3.5
Dividend paid	—	0.0	0.0	0.0	0.0	0.0
Total assets	—	—	109.6	90.5	123.7	148.2
Equity	—	—	74.0	65.6	98.1	122.7

Quarterly performance

last 24 quarters · ₹ crore

showing latest 8 of 24 periods

	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	29.2	20.9	14.6	21.7	21.0	19.0	28.5	17.1	18.1	15.3	12.6	15.7	24.3	21.8	17.7	17.9	20.8	20.5	23.3	25.5	23.4	16.6	20.2	23.0
Operating profit	5.3	-0.7	-3.9	-0.4	-4.6	-6.4	-3.9	-8.6	-9.2	-8.6	-0.1	0.0	1.7	1.1	0.4	0.3	1.5	1.6	1.5	3.1	2.5	0.7	0.7	1.9
Operating margin	18.3%	-3.2%	-26.9%	-1.7%	-21.9%	-33.6%	-13.7%	-50.2%	-51.1%	-55.9%	-1.0%	0.1%	7.1%	5.1%	2.1%	1.6%	7.3%	7.7%	6.6%	12.3%	10.7%	4.4%	3.4%	8.1%
Other income	0.5	0.0	0.1	0.7	0.6	0.4	0.2	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.7	0.1	0.2	0.0	0.6	0.2	0.4	0.1	0.4	0.2
Interest	0.8	0.8	0.7	0.8	0.8	0.7	0.8	0.6	0.6	0.8	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.2	0.1	0.2
Depreciation	1.7	1.7	1.7	1.8	1.7	1.9	1.9	2.0	2.3	2.3	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Profit before tax	3.4	-3.1	-6.3	-2.2	-6.5	-8.6	-6.5	-11.2	-12.0	-11.2	-0.7	-0.5	1.2	0.6	0.3	-0.2	1.0	0.9	1.5	2.6	2.2	0.3	0.6	1.4
Tax	0.0	0.0	10.4	-0.9	-1.8	-1.2	-0.6	-1.8	-3.9	-1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
Net profit	0.0	-2.6	-17.3	-1.1	-4.8	-7.8	-3.6	-9.4	-4.7	-9.5	-4.3	-4.5	0.0	-3.9	-9.6	-2.4	-4.0	-2.1	-1.5	9.6	8.0	5.5	1.5	-1.8
EPS ₹	1.35	-1.03	6.93	-0.47	-1.97	-3.14	-1.46	-3.80	-3.19	-2.03	-1.74	-1.75	-0.64	-1.51	-3.77	-0.94	-1.51	-0.82	-0.54	3.25	2.71	1.87	0.52	-0.61
Revenue YoY	—	—	—	—	-28.1%	-9.1%	94.7%	-21.1%	-13.9%	-19.5%	-55.7%	-8.3%	34.5%	42.2%	40.5%	14.2%	-14.5%	-5.7%	31.6%	42.3%	12.8%	-19.2%	-13.3%	-10.0%
Profit YoY	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-118.7%

Earlier results (standalone, Sep '11 – Jun '20)

₹ crore · from BSE, before the NSE XBRL filings begin

Brooks Laboratories Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†	FY20†
Revenue	85.3	85.2	80.0	62.3	56.9	55.0	69.7
Operating profit	8.5	6.8	11.1	5.6	-8.9	-8.4	-3.9
Operating margin	10.0%	7.9%	13.8%	9.0%	-15.6%	-15.3%	-5.5%
Other income	—	2.4	1.6	0.2	0.2	2.9	0.4
Interest	0.1	0.4	0.8	1.0	2.4	3.0	3.4
Depreciation	0.8	1.1	1.2	1.7	6.4	6.5	6.7
Profit before tax	7.6	10.4	10.8	3.1	-17.5	-14.9	-13.5
Tax	0.3	0.9	0.2	1.1	-3.8	-0.1	10.9
Net profit	7.2	9.5	10.6	2.0	-13.8	-14.8	-24.4

Quarters

showing latest 8 of 35 periods

	SEP '11†	DEC '11†	MAR '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†	JUN '19†	SEP '19†	DEC '19†	MAR '20†	JUN '20†
Revenue	14.4	15.5	14.5	20.6	23.2	22.3	22.1	25.2	19.1	18.8	16.5	21.6	23.7	23.5	18.0	20.5	20.9	20.7	15.4	16.1	16.5	14.3	8.3	13.2	20.9	14.5	10.7	14.1	15.1	15.2	16.8	14.2	19.9	18.8	12.5
Operating profit	2.9	2.9	3.0	2.7	2.7	2.6	2.2	2.2	1.7	2.4	1.1	1.5	2.1	2.0	1.6	2.7	3.0	3.8	2.9	1.7	1.3	-0.3	-3.5	-2.7	-1.0	-1.7	-3.6	-1.5	-0.9	-2.4	-0.1	-1.9	-0.9	-0.8	-0.2
Operating margin	20.4%	18.3%	20.7%	12.9%	11.7%	11.7%	10.0%	8.7%	8.9%	12.8%	6.7%	7.1%	8.7%	8.7%	9.1%	13.0%	14.5%	18.1%	18.9%	10.5%	7.7%	-2.0%	-41.3%	-20.5%	-4.8%	-12.0%	-33.8%	-10.6%	-5.9%	-16.0%	-0.8%	-13.6%	-4.8%	-4.5%	-2.0%
Other income	0.1	0.4	0.2	0.5	0.5	5.6	—	—	—	—	0.7	0.6	0.7	0.4	0.4	0.4	0.5	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.3	0.1	0.1	2.5	0.1	0.1	0.1	0.2	0.1
Interest	0.3	0.0	0.4	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.1	0.3	0.4	0.1	0.2	0.2	0.2	0.3	0.5	0.6	0.7	0.7	0.7	0.8	0.8	0.7	0.8	0.8	0.9	0.9	0.8
Depreciation	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.7	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.6	1.6	1.6	1.6	1.9	2.0
Profit before tax	2.6	3.0	2.6	2.9	3.1	8.1	2.0	2.0	1.5	2.2	1.5	3.9	2.3	2.7	1.6	2.6	2.9	3.7	2.5	1.1	0.7	-1.2	-5.4	-4.8	-3.3	-4.0	-5.6	-3.8	-3.2	-2.3	-2.5	-4.3	-3.4	-3.4	-2.9
Tax	0.1	0.1	0.1	-0.0	0.1	2.7	0.1	0.1	0.1	0.2	-0.1	0.1	0.5	0.4	0.1	0.9	0.1	-0.9	0.8	0.4	0.2	-0.4	0.4	-1.8	-0.7	-1.7	-1.9	-1.8	-1.1	4.6	1.3	-2.4	-0.6	12.5	0.0
Net profit	2.5	3.0	2.5	2.9	3.0	5.4	1.9	1.9	1.4	2.0	1.5	3.8	1.8	2.3	1.5	1.7	2.8	4.6	1.6	0.7	0.5	-0.9	-5.9	-3.0	-2.6	-2.3	-3.7	-2.0	-2.1	-6.9	-3.7	-1.9	-2.8	-16.0	-2.9
EPS ₹	4.72	3.12	2.62	7.14	7.33	4.48	1.18	1.17	0.87	1.23	0.95	2.35	1.10	1.45	0.94	1.05	1.73	2.86	1.01	0.45	0.29	-0.55	-3.63	-1.87	-1.62	-1.40	-0.83	-1.24	-1.33	-4.29	-2.31	-1.12	-1.67	-9.07	-1.17
Revenue YoY	—	—	—	43.6%	49.5%	54.0%	—	22.2%	-17.6%	-15.6%	-25.6%	-14.4%	23.7%	24.9%	9.2%	-5.1%	-11.9%	-12.0%	-14.3%	-21.3%	-21.0%	-30.8%	-45.8%	-18.2%	26.7%	1.4%	27.8%	7.1%	-27.7%	4.4%	57.6%	0.4%	31.7%	24.1%	-25.9%
Profit YoY	—	—	—	14.1%	1.0%	117.6%	—	-34.7%	-52.5%	-63.2%	-19.9%	100.0%	26.1%	17.0%	-1.3%	-55.3%	55.9%	97.4%	8.6%	-57.6%	-82.8%	-119.0%	-458.5%	-519.4%	-645.8%	—	—	—	—	—	—	—	—	—	—

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 21 periods

	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	—	—	—	—	—	-31.7%	-33.9%	-37.7%	-31.0%	-23.1%	-16.0%	-27.4%	-24.2%	-33.5%	-30.6%	-10.2%	2.1%	12.1%	18.7%	20.0%	10.7%
ROCE	—	—	—	—	—	-34.5%	-37.0%	-41.3%	-28.5%	-12.1%	1.5%	3.4%	3.8%	3.9%	4.5%	4.1%	6.9%	6.9%	6.3%	5.1%	4.1%
Net margin	-24.3%	-33.0%	-40.6%	-19.2%	-29.9%	-30.8%	-34.4%	-44.1%	-37.2%	-26.9%	-17.0%	-22.6%	-19.5%	-25.4%	-23.5%	-12.1%	2.3%	15.1%	24.3%	28.6%	15.8%
EBITDA margin	0.5%	-12.2%	-20.0%	-16.9%	-27.4%	-34.0%	-38.4%	-42.0%	-29.0%	-10.2%	3.7%	4.1%	4.3%	4.2%	4.9%	5.9%	8.6%	9.5%	8.9%	8.2%	7.0%
Debt / equity	—	—	—	—	—	0.28	0.28	0.08	0.08	0.04	0.04	0.08	0.08	0.12	0.12	0.06	0.06	0.06	0.06	0.06	0.06
Interest coverage	-1.70	-5.01	-6.94	-6.73	-10.14	-12.54	-13.39	-15.09	-13.12	-7.72	1.71	2.85	3.25	2.72	2.93	4.14	6.22	7.55	7.70	7.99	7.18
Asset turnover	—	—	—	—	—	0.39	0.38	0.58	0.56	0.64	0.70	0.88	0.90	0.86	0.84	0.67	0.73	0.66	0.63	0.58	0.56

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 8 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	24.7	24.7	26.2	26.2	26.2	29.5	29.5	29.5
Other equity / reserves	55.5	49.2	52.9	39.3	33.0	68.7	86.2	93.2
Total equity	80.2	74.0	79.1	65.6	59.2	98.1	115.7	122.7
Borrowings	22.6	5.7	3.5	5.0	7.2	6.1	6.5	7.3
Current liabilities	60.1	33.0	24.4	23.1	28.7	22.8	21.7	21.8
Non-current liabilities	10.9	2.6	2.5	1.8	3.2	2.8	2.6	3.7
Total assets	209.8	109.6	106.0	90.5	91.1	123.7	139.9	148.2
Property, plant & equipment	108.7	14.0	13.4	13.1	12.8	12.5	13.3	13.4
Capital work-in-progress	24.6	0.0	0.0	0.0	0.0	1.5	0.9	1.2
Investments	0.3	64.0	58.2	42.9	35.8	73.5	86.2	92.3
Inventories	21.9	11.3	10.2	9.6	9.5	9.2	7.7	11.0
Receivables	15.8	12.8	15.8	16.3	23.7	20.0	25.2	16.1
Cash & equivalents	0.1	0.0	0.2	0.1	0.2	0.0	0.0	6.6

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	-37.4	-14.5	-9.7	2.5	9.3
Cash from investing	-24.9	0.5	0.2	-46.0	-2.9
Cash from financing	64.1	11.4	9.6	43.4	0.2
Capex	27.6	0.5	0.4	0.9	3.5
Free cash flow	-65.0	-15.0	-10.1	1.6	5.8
Dividends paid	0.0	0.0	0.0	0.0	0.0

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹13.4 cr9%

CWIP

₹1.2 cr1%

Investments

₹92.3 cr62%

Inventories

₹11.0 cr7%

Receivables

₹16.1 cr11%

Cash & equivalents

₹6.6 cr4%

Other assets

₹7.5 cr5%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Brooks Laboratories Limited	186	63.25	14.1	1.52	10.7%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+7.6%

6 months+20.4%

1 year-40.3%

3Y CAGR-17.7%

5Y CAGR-11.6%

10Y CAGR-9.6%

50-day avg₹62.75

200-day avg₹63.18

RSI (14)42

FAQs

What is the share price of Brooks Laboratories Limited?

Brooks Laboratories Limited (BROOKS) closed at ₹63.25 on NSE on 06 Nov 2026.

What is the market cap of Brooks Laboratories Limited?

₹186 crore at the latest close.

What is the P/E ratio of Brooks Laboratories Limited?

14.1, on trailing-twelve-month earnings from its filings.

How fast is Brooks Laboratories Limited growing?

Brooks Laboratories Limited: revenue has compounded at 10.7% a year over three years. Latest-quarter revenue is down 10.0% year on year, profit down 118.7%.

How profitable is Brooks Laboratories Limited?

On a trailing-twelve-month basis return on equity is 10.7%, return on capital employed 4.1%, operating margin 7.0%, net margin 15.8%.

How much debt does Brooks Laboratories Limited have?

Brooks Laboratories Limited is lightly geared: debt to equity is 0.06 with borrowings of ₹7 cr against cash of ₹7 cr (balance sheet of 2026-03-31). Operating profit covers interest 7.2 times.

Financials parsed from Brooks Laboratories Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '20, annual from FY21, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.